ABSTRACT
Background There remains substantial variation in the reported prevalence of CKD in Australia. Using a large, nationally-representative general practice data source in Australia, we determined the contemporary prevalence and staging of CKD in Australian primary care.
Methods We performed a retrospective, community-based observational study using healthcare data from MedicineInsight, a national general practice data source in Australia. The study included all adults with ≥1 visit to a general practice participating in the MedicineInsight program and ≥1 serum creatinine measurement (with or without a urine albumin-to-creatinine ratio [UACR] measurement) between 1 January 2011 and 31 December 2020; n=2,720,529 patients). The prevalence of CKD was estimated using three definitions: (1): an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 or an eGFR ≥60 mL/min/1.73m2 with a UACR ≥2.5 mg/mmol for males and ≥3.5 mg/mmol for females (definition 1), (2) two consecutive eGFR measures <60 mL/min/1.73m2 at least 90 days apart or an eGFR ≥60 mL/min/1.73m2 with a UACR ≥2.5 mg/mmol for males and ≥3.5 mg/mmol for females (definition 2), and (3) two consecutive eGFR measures <60 mL/min/1.73m2 at least 90 days part and/or two consecutive UACR measures ≥2.5 mg/mmol for males and ≥3.5 mg/mmol for females at least 90 days apart (definition 3). Patient sociodemographic characteristics including comorbid conditions were assessed across the three definitions.
Results The prevalence of CKD in the study cohort progressively increased over the 10-year study period, irrespective of the method used to define CKD. The annual prevalence of CKD varied across the three CKD definitions, with definition 1 resulting in the highest estimates. In 2020, the prevalence of CKD in the study cohort was 8.4% (n=123,988), 4.7% (n=69,110) and 3.1% (n=45,360) using definitions 1, 2 and 3, respectively. The number of patients with UACR measurements was low such that, among those identified as having CKD in 2020, only 3.8%, 3.2% and 1.5% respectively, had both eGFR and UACR measurements available in the corresponding year. Patients in whom both eGFR and UACR measurements were available mostly had moderate or high risk of CKD progression by local and international CKD guidelines (83.6%, 80.6% and 76.2%, respectively). Comorbid burden in patients with CKD was also frequently observed (coronary heart disease: 28.9%, type 2 diabetes: 38.5%, heart failure: 17.9%; using CKD definition 3).
Conclusion In this large, nationally representative study, we observed an increasing trend in CKD prevalence in primary care settings in Australia. Most patients with CKD were at moderate to high risk of CKD progression with a significant comorbid burden including coronary heart disease and diabetes. These findings highlight the need for early detection and effective management to slow progression of CKD.
Competing Interest Statement
This study was supported by an unrestricted research grant from Boehringer Ingelheim. An independent study steering committee was responsible for all aspects of the study conduct including study design, analysis, interpretation of study findings, reporting and the decision to submit the manuscript for publication. MJ is responsible for research projects that have received unrestricted research funding from Boehringer Ingelheim. BLN has received fees for travel support, advisory boards, scientific presentations and steering committee roles from AstraZeneca, Bayer, Boehringer Ingelheim, Cambridge Healthcare Research, Janssen and Medscape with all honoraria paid to his institution. SVB has received research grants from the National Health and Medical Research Council of Australia, advisory board fees from Bayer, AstraZeneca and Vifor Pharma, speaker's honoraria from Bayer, AstraZeneca, Vifor Pharma and Pfizer and nonfinancial research support from Bayer, all fees paid to The George Institute for Global Health. VP has received fees for advisory boards, steering committee roles, or scientific presentations from AbbVie, Astellas, AstraZeneca, Bayer, Baxter, BMS, Boehringer Ingelheim, Dimerix, Durect, Eli Lilly, Gilead, GSK, Janssen, Merck, Mitsubishi Tanabe, Mundipharma, Novartis, Novo Nordisk, Pfizer, Pharmalink, Relypsa, Retrophin, Sanofi, Servier, Tricida and Vitae. PR has no financial disclosures.
Funding Statement
This study is based on data from MedicineInsight (project 2020-004), a national general practice data program developed by NPS MedicineWise and managed by the Australian Commission on Safety and Quality in Health Care. MedicineInsight extracts and collates longitudinal, de-identified, patient health data from the clinical information systems of consenting general practices across Australia. This study was supported by an unrestricted research grant from Boehringer Ingelheim. MJ is supported by the Scientia Program at the Faculty of Medicine and Health, UNSW Sydney, Australia.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the MedicineInsight Data Governance Committee (2020-004) and Research Ethics Review Committee of the Sydney Local Health District, NSW, Australia (X21-0428, 2020/ETH00963). The study abides by the RECORD extension of the STROBE reporting guidelines15.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The current study is based on data from MedicineInsight, a national general practice data source developed by NPS MedicineWise and managed by the Australian Commission on Safety and Quality in Health Care. All relevant data are within the manuscript and its supplementary appendix.